1. Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus
- Author
-
Rodolfo M. Alpizar-Rivas, Stephanie M. Hon, and Harrison W. Farber
- Subjects
Pulmonary Arterial Hypertension ,medicine.medical_specialty ,business.industry ,Hypertension, Pulmonary ,Human immunodeficiency virus (HIV) ,HIV ,Improved survival ,HIV Infections ,General Medicine ,medicine.disease ,medicine.disease_cause ,Pulmonary hypertension ,Treatment management ,polycyclic compounds ,medicine ,Humans ,In patient ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business - Abstract
It is important to recognize and treat human immunodeficiency virus-associated pulmonary arterial hypertension (HIV-PAH) because of the associated morbidity and mortality. With the introduction of antiretroviral therapies (ART), improved survival has changed the focus of treatment management from immunodeficiency-related opportunistic infections to chronic cardiovascular complications, including HIV-PAH. The 2018 6th World Symposium of Pulmonary Hypertension recommended a revised definition of PAH that might result in a greater number of patients with HIV-PAH; however, the implication of this change is not yet clear. Here, we review the current literature on the diagnosis, management, and outcomes of patients with HIV-PAH.
- Published
- 2022